News: Simtuzumab

We provide the latest news and info on Simtuzumab


Motley Fool

Your 2016 Guide to Investing in Gilead Sciences Stock
Motley Fool
Overall, Gilead Sciences' NASH program includes mid-stage studies of simtuzumab and GS-4977, and a phase 1 study of GS-9674. Finally, Gilead Sciences has phase 2 studies underway in Crohn's disease, ulcerative colitis, and rheumatoid arthritis, and ...

and more »

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


Gilead Sciences (GILD) Presents at 2016 UBS Global Healthcare Brokers Conference (Transcript)
Seeking Alpha
Thank you. I'm Mark Goodman, I do pharma, specialty pharma and I guess sometimes biotech at UBS. And thank you very much for joining us here. We're lucky to have Gilead next and I think everybody knows Norbert Bischofberger, who has been at the ...

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


The Pharma Letter (registration)

Strike two: Gilead chalks up another setback for top pipeline prospect simtuzumab
FierceBiotech
Gilead has racked up its second straight setback on simtuzumab, scrapping a mid-stage study for idiopathic pulmonary fibrosis after a data monitoring group concluded that the drug wasn't working as expected. The drug, which blocks the LOXL2 enzyme, has ...
Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary FibrosisBusiness Wire (press release)
Gilead stops Phase II trial of simtuzumabThe Pharma Letter (registration)
Gilead Sciences (GILD) Terminates Phase 2 Study of Simtuzumab in IPFStreetInsider.com
San Francisco Business Times (blog) -ValueWalk -Wall Street Journal
all 108 news articles »

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


Motley Fool

3 Key Pipeline Developments for Gilead Investors to Watch
Motley Fool
Simtuzumab, an antibody which blocks the LOXL2 enzyme, is currently being evaluated in a phase 2 study for NASH. According to the National Institutes of Health, NASH, also known as the "silent killer," is a fatty liver disease that affects as many as ...

and more »

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


Phase II Trial for Gilead's IPF Therapy Simtuzumab Terminated After DMC Recommendation
Pulmonary Fibrosis News
Gilead Sciences, Inc. recently announced in a press release that it is stopping its RAINIER Phase II clinical trial testing the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF), noting that the ...

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


Gilead Halts Study of Simtuzumab in Patients With Pulmonary Fibrosis
Managed Care magazine
Gilead Sciences has announced that the company is stopping its mid-stage trial of the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis. The decision follows an analysis of unblinded efficacy and safety ...

and more »

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...


Gilead (GILD) Simtuzumab Advancement in NASH an 'Incremental Positive', Jefferies Says
StreetInsider.com
Jefferies analyst Brian Abrahams said they have confirmed that the interim 48-week futility analysis for antifibrotic pipeline antibody simtuzumab in NASH has been completed and the ph.II studies are continuing. The sees this as an incremental positive ...

and more »

Published on Tuesday 24th of May 2016 01:00:36 AM Read more...

Our Services

Do not forget to check the lastest products and auctions related to Simtuzumab as well as our free videos and podcasts.

best Simtuzumab products current Simtuzumab auctions current Simtuzumab videos listen to Simtuzumab podcasts